Ensuring the health and safety of the workforce – while maintaining business as usual – is a delicate balance in the face of the COVID-19 pandemic.
In this episode of our Coronavirus Special Edition Series, Syneos Health CEO Alistair Macdonald discusses the unique decisions to be made as a pharmaceutical organization practicing corporate responsibility in the name of public health.
Stay tuned for more installments of the Coronavirus Special Edition Series, which will explore, from an operational standpoint, the impact of COVID-19 on the biopharma industry, the challenges for rapid R&D in an outbreak environment, and the opportunities to leverage technology and innovation to address these critical issues. Additional materials and insights can also be found in our COVID-19 Resource Center.
